Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol 2006 Apr;16(2):137-49

Date

12/27/2005

Pubmed ID

16376101

DOI

10.1016/j.semcancer.2005.11.007

Scopus ID

2-s2.0-31644451518   55 Citations

Abstract

Suppressor/regulatory T cells were first shown to have an impact on cancer progression in experimental tumor models during the 1970s. However, the lack of specific markers hindered mechanistic investigations, and skepticism grew in the scientific community due to variability in cell populations and reported functions. The identification of regulatory CD4(+)CD25(+) T cells has generated a great deal of renewed interest in cells that have immune regulatory properties. This article will provide a brief historical review of suppressor T cells and cancer, experimental and clinical evidence that CD4(+)CD25(+) natural regulatory T cells play a role in cancer progression, and briefly discuss current strategies to inhibit these cells in an effort to enhance cancer immunotherapy.

Author List

Orentas RJ, Kohler ME, Johnson BD

Author

Bryon D. Johnson PhD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

CD4 Antigens
Humans
Immune Tolerance
Immunosuppression
Neoplasms
Receptors, Interleukin-2
T-Lymphocytes, Regulatory
jenkins-FCD Prod-406 0f9a74600e4e79798f8fa6f545ea115f3dd948b2